ABSTRACT
Introduction: We conducted a multi-centric phase II study to evaluate the tumor response and safety of the combination of vinorelbin and docetaxel in treatment of metastatic breast cancer patients
Patients and methods: Forty one metastatic breast cancer patients, who had at least one measurable lesion and had not been treated for metastasis before, were enrolled from March 2006 to June 2009. Treatment contained vinorelbine 25mg/m2 IV and docetaxel 30mg/m2 at day 1 and 8. Cycles were repeated every 21 days for 6 cycles. We evaluated response to chemotherapy every three weeks and toxicity every week
Results: The mean age of patients was 50.4 years [range 30-81]. Twenty eight patients [68.2%] had received prior neoadjuvant anthracycline based chemotherapy. No patient had received adjuvant chemotherapy within the last 3 months. Twenty four patients [58.3%] had two or more metastatic sites. Thirty six patients were evaluable for their response. An objective tumor response [either complete response or partial response] was achieved in 32 [88.8%] and complete response was seen in 9 [25%] patients. Thirteen patients [31.6%] developed grade 3-4 neutropenia and neutropenic fever was reported in 11 [26.8%]. Grade 3 anemia was observed in 1 patient [2.4%]. No grade 4 non-hematological toxicity was noted and the most frequent grade 3 non-hematological toxicities were hair loss [39%], stomatitis [7.3%] and diarrhea [4.8%]. Median time to progression was 7 months and median overall survival was 11 months
Conclusion: Vinorelbine-docetaxel combination shows a considerable tumor response and manageable toxicity as the first line treatment for metastatic breast cancer. It seems logical to conduct phase III trials to further evaluate this regimen
ABSTRACT
Cervical cancer is one of the major causes of cancer and death among women aged 40 to 60 in developing countries. There is some difference, however, in the incidence of this cancer in Iranian women compared to women living in western and south-east Asian countries. We aimed at investigating the epidemiologic aspects and treatment results of cervical cancer among Iranian patients. Medical records of patients with cervical cancer who were referred to Mortazavi Radiation Oncology Center [Imam Hossein Hospital] between 2000 and 2004 were evaluated retrospectively. Clinical data such as stage of the disease, type pf chemotherapy, radiation technique and sequence of treatment was recorded. A total of 220 patients with a median age of 55 years [range: 28 to 89] were studied. The majority of them [37.3%] were referred with stage IIB of the disease. Other stages, in order of frequency, were IIA, IIIA and IB. Most of the patients [74%] were treated with two opposed field radiotherapy with a dose of 50 Gy or less [64%]. Disease recurred in 46 patients [21%], 153 patients [74%] received two opposed field radiotherapy and 54 [36%] patients were treated with four fields. On the other hand, 113 patients [55%] did not receive brachytherapy, 36 [18%] only received ovoid brachytherapy and 56 [27%] were treated with ovoid and tandem brachytherapy. Recurrence was more prevalent if the radiotherapy dose was less than 50 Gy and also in patients treated with four-field box technique. The most frequent site of recurrence was pelvic area [71%]. Our report revealed that most of the patients in Iran are diagnosed in advanced stages, a finding that can influence treatment results. Also, using external beam radiotherapy techniques, accessibility to brachytherapy devices and better patient support may improve treatment results